BR112022007595A2 - Métodos para tratar doença de alzheimer - Google Patents

Métodos para tratar doença de alzheimer

Info

Publication number
BR112022007595A2
BR112022007595A2 BR112022007595A BR112022007595A BR112022007595A2 BR 112022007595 A2 BR112022007595 A2 BR 112022007595A2 BR 112022007595 A BR112022007595 A BR 112022007595A BR 112022007595 A BR112022007595 A BR 112022007595A BR 112022007595 A2 BR112022007595 A2 BR 112022007595A2
Authority
BR
Brazil
Prior art keywords
disease
methods
treat alzheimer
alzheimer
treat
Prior art date
Application number
BR112022007595A
Other languages
English (en)
Inventor
Budd Haeberlein Samantha
Tian Ying
Nisenbaum Laura
Rajagovindan Raj
Dent Gersham
Beaver John
Plowey Edward
Bussiere Thierry
Nitsch Roger
Original Assignee
Biogen Ma Inc
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Neurimmune Ag filed Critical Biogen Ma Inc
Publication of BR112022007595A2 publication Critical patent/BR112022007595A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODOS PARA TRATAR DOENÇA DE ALZHEIMER. A presente invenção refere-se a métodos para tratar doença de Alzheimer em um ser humano com necessidade dos mesmos que compreendem a administração de múltiplas doses de um anticorpo anti-beta-amilóide (por exemplo, aducanumabe) ao indivíduo.
BR112022007595A 2019-10-22 2020-10-21 Métodos para tratar doença de alzheimer BR112022007595A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112022007595A2 true BR112022007595A2 (pt) 2022-08-23

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007595A BR112022007595A2 (pt) 2019-10-22 2020-10-21 Métodos para tratar doença de alzheimer

Country Status (13)

Country Link
US (1) US20220372123A1 (pt)
EP (1) EP4048695A1 (pt)
JP (1) JP2022553329A (pt)
KR (1) KR20220084095A (pt)
CN (1) CN114599393A (pt)
AU (1) AU2020371612A1 (pt)
BR (1) BR112022007595A2 (pt)
CA (1) CA3158513A1 (pt)
CO (1) CO2022004902A2 (pt)
IL (1) IL292363A (pt)
JO (1) JOP20220092A1 (pt)
MX (1) MX2022004678A (pt)
WO (1) WO2021081101A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023149970A1 (en) * 2022-02-02 2023-08-10 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024089620A1 (en) * 2022-10-25 2024-05-02 Institute For Basic Science (Ibs) Extracranial methods for facilitating cerebrospinal fluid drainage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029481B1 (ru) 2007-01-05 2018-04-30 Юнивэсэти Оф Цюрих Способ получения человеческого рекомбинантного антитела, специфично связывающего вариант эндогенного белка, формирующий аномальные патологические белковые структуры путем агрегации, олигомеризации или образования фибрилл
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3464350A1 (en) * 2016-06-07 2019-04-10 Biogen International Neuroscience GmbH Methods for treating alzheimer's disease

Also Published As

Publication number Publication date
JP2022553329A (ja) 2022-12-22
IL292363A (en) 2022-06-01
MX2022004678A (es) 2022-08-15
JOP20220092A1 (ar) 2023-01-30
US20220372123A1 (en) 2022-11-24
CN114599393A (zh) 2022-06-07
AU2020371612A1 (en) 2022-05-19
KR20220084095A (ko) 2022-06-21
WO2021081101A1 (en) 2021-04-29
CO2022004902A2 (es) 2022-07-08
CA3158513A1 (en) 2021-04-29
EP4048695A1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
EA202092154A1 (ru) Комбинированная терапия
BR112018075300A2 (pt) métodos para tratamento do mal de alzheimer
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112018073843A2 (pt) anticorpos de peptídeo beta amiloide anti-n3pglu e usos dos mesmos
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112019001193A2 (pt) uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele
AR119159A1 (es) Tratamientos de angioedema
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
BR112022000231A2 (pt) Novos métodos
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
BR112019011350A2 (pt) terapia de combinação
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
BR112021020601A2 (pt) Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina